Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer

Takashi Nomizo, Haruka Yamamoto, Tsunetaka Murayama, Hiroko Fukata, Yasukiyo Nakamura, Mami Sonomura, Aika Okuno, Naoki Kanda, Chihiro Watanabe, Hideo Kita

Article ID: 1386
Vol 6, Issue 1, 2022

VIEWS - 1109 (Abstract) 460 (PDF)

Abstract


It has been less than a decade since immune checkpoint inhibitors became the mainstay of lung cancer treatment, and 2020 saw the advent of the era of complex immune checkpoint inhibitors. Although clinical trials have shown that the therapeutic effects of complex immune checkpoint inhibitors are favorable, they are associated with an increase in adverse events. The use of combined immune checkpoint inhibitors in clinical practice has progressed slowly, and the frequency and types of adverse events they cause remain unclear. Here we report the adverse events of six patients with lung cancer treated with regimens containing nivolumab and ipilimumab in 2021. Four of the six patients had grade 3 or higher adverse events, including one patient with lung injury and one patient with skin injury, both of whom died. The timing and nature of the adverse events were difficult to predict.


Keywords


Lung Cancer; Immune Checkpoint Inhibitors; Nivolumab; Ipilimumab; 9LA; Immune-related Adverse Events

Full Text:

PDF


References


1. Cancer Facts & Figures 2020 [Internet]. Atlanta: American Cancer Society; 2020. p. 1–76 [cited 2021 Nov]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf

2. The editorial board of the Cancer Statistics in Japan (editors). Cancer Statistics in Japan 2021. Tokyo, Japan: Foundation for Promotion of Cancer Research (FPCR); 2021. p. 1–146. Available from: https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2021.pdf).

3. Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. The Oncologist 2018; 23(9): 991–997. doi: 10.1634/theoncologist.2018-0174.

4. Hellmann MD, Paz-Ares L, Caro RB, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. New England Journal of Medicine 2019; 381(21): 2020–2031. doi: 10.1056/NEJMoa1910231

5. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. The Lancet Oncology 2021; 22(2): 198–211. doi: 10.1016/S1470-2045(20)30641-0

6. Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from Pharmacovigilance. Targeted Oncology 2020; 15(4): 449–466. doi: 10.1007/s11523-020-00738-6.

7. Logan IT, Zaman S, Hussein L, et al. Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: A case report and literature review. Journal of Immunotherapy 2020; 43(3): 89–92. doi: 10.1097/CJI.0000000000000302

8. Gopee NH, Gourley AM, Oliphant TJ, et al. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors. Dermatology Online Journal 2020; 26(8): 1–5. doi: 13030/qt8fc428f6. PMID: 32941713.

9. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2019; 17(3): 255–289. doi: 10.6004/jnccn.2019.0013

10. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine 2018; 378(2): 158–168. doi: 10.1056/NEJMra1703481.

11. Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis 2018; 101(1): E15–E21. PMID: 29529123

12. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. Journal of Thoracic Oncology 2021; 16(11): 1909–1924. doi: 10.1016/j.jtho.2021.07.009

13. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England Journal of Medicine 2018; 378(22): 2078–2092. doi: 10.1056/NEJMoa1801005

14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019; 381(16): 1535–1546. doi: 10.1056/NEJMoa1910836




DOI: https://doi.org/10.24294/ti.v6.i1.1386

Refbacks

  • There are currently no refbacks.


Copyright (c) 2022 Takashi Nomizo, Haruka Yamamoto, Tsunetaka Murayama, Hiroko Fukata, Yasukiyo Nakamura, Mami Sonomura, Aika Okuno, Naoki Kanda, Chihiro Watanabe, Hideo Kita

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.